Cencora, Inc. earns a Buy rating with a $337 fair value. Learn how its specialty drug focus and strategic investments drive ...

Healthcare distributor Cencora (NYSE:COR) reported Q2 CY2025 results , with sales up 8.7% year on year to $80.66 billion. Its ...

Q3 2025 Management View Robert P. Mauch, President and CEO, opened by highlighting "Cencora delivered strong performance with adjusted operating income growth of 21% and adjusted diluted EPS growth of ...

Cencora, Inc. (NYSE:COR) on Wednesday reported third-quarter 2025 sales increased 8.7% to $80.66 billion, beating the ...

COR benefits from strong specialty and GLP-1 demand, but Q3 results may face pressure from international weakness.

Shares of Cencora Inc. COR shed 2.93% to $283.78 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.73% to 6,345.06 and ...

Cencora, Inc. ( NYSE: COR) Q3 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Bennett S. Murphy - Senior VP, Head of Investor Relations & Treasury James F. Cleary - Executive VP & CFO Robert P ...

Cencora’s forward-looking guidance remains optimistic, with expectations of substantial growth. The company anticipates a 15% to 16% increase in adjusted diluted EPS and consolidated operating income.

Texas-headquartered Mckesson expects per-share profit in the range of $37.10 to $37.90 for fiscal 2026, compared to its ...

Shares of Cencora Inc. COR slipped 1.96% to $286.08 Thursday, on what proved to be an all-around rough trading session for ...